Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial

The Lancet

Volumn 378, Issue 9787, 2011, Pages 229-237

  Cohen, Calvin J ^a   Andrade Villanueva, Jaime ^b   Clotet, Bonaventura ^c   Fourie, Jan ^d   Johnson, Margaret A ^e   Ruxrungtham, Kiat ^f   Wu, Hao ^g   Zorrilla, Carmen ^h   Crauwels, Herta ⁱ   Rimsky, Laurence T ⁱ   Vanveggel, Simon ⁱ   Boven, Katia ^j  

^a Boston Community Research Initiative of New England   (United States)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Dr J Fourie Medical Centre ^*  (South Africa)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF PUERTO RICO   (Puerto Rico)

ⁱ Tibotec   (Belgium)

^j Tibotec   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; RILPIVIRINE;

ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79960358849     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60983-5     Document Type: Article

References (35)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. Jan 10, 2011; 1-166 http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed May 5, 2011).
2. MA Thompson, JA Aberg, P Cahn et al. Antiretroviral treatment of adult HIV infection 2010 Recommendations of the International AIDS Society - USA Panel JAMA 304 2010 321 333
3. JA Pérez-Molina Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients HIV Clin Trials 3 2002 279 286
4. FDA label for Sustiva (efavirenz) capsules and tablets Bristol-Myers Squibb Company, November, 2010 http://packageinserts.bms.com/pi/pi-sustiva.pdf (accessed May 5, 2011).
5. FDA label for Edurant (rilpivirine) tablets http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/202022s000lbl.pdf 2011 (accessed May 28, 2011).
6. F Goebel, A Yakovlev, AL Pozniak et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects AIDS 20 2006 1721 1726 (Pubitemid 44299363)
7. AL Pozniak, J Morales-Ramirez, E Katabira et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial AIDS 24 2010 55 65
8. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. TMC278 shows favorable tolerability and non-inferior efficacy compared to efavirenz over 192 weeks in HIV-1-infected treatment-naive patients. 19th Annual Canadian Conference on HIV/AIDS Research; Saskatoon, Canada; May 13-16, 2010. Abstract 7214.
9. Desmidt M, Willems B, Dom P, et al. Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278. 12th European AIDS Conference; Cologne, Germany; Nov 11-14, 2009. Abstract PE7.1/4.
10. J-M Molina, P Cahn, B Grinsztejn et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial Lancet 378 2011 238 246
11. L Tambuyzer, H Azijn, LT Rimsky et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors Antivir Ther 14 2009 103 109
12. Clinical considerations for accelerated and traditional approval of antiretroviral drugs using plasma HIV RNA measurements - guidance for industry 2002 US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Rockville, MD, USA
13. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events Version 1 http://rsc.tech-res.com/ safetyandpharmacovigilance December 28, 2004 (accessed June 24, 2011).
14. AS Levey, JP Bosch, J Breyer Lewis, T Greene, N Rogers, D Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
15. FJ Hoek, FAW Kemperman, RT Krediet A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate Nephrol Dial Transplant 18 2003 2024 2031 (Pubitemid 37220307)
16. R Manfredi, L Calza, F Chiodo Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study J Acquir Immune Defic Syndr 35 2004 492 502 (Pubitemid 38420658)
17. RM Gulick, HJ Ribaudo, CM Shikuma et al. Triple-nucleoside regimens versus efavirenz-containing regiments for the initial treatment of HIV-1 infections N Engl J Med 350 2004 1850 1861 (Pubitemid 38917251)
18. F Pulido, JR Arribas, JM Miró et al. Clinical, virological and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive subjects with advanced HIV infection J Acquir Immune Defic Syndr 35 2004 343 350 (Pubitemid 38332794)
19. R van Leeuwen, C Katlama, RL Murphy et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected subjects AIDS 17 2003 987 999 (Pubitemid 36549710)
20. I Suarez Lozano, M Garrido, P Viciana et al. How ART works in naive subjects in clinical practice: ACTG 384 was mimicked in an observational database (Spanish VACH Cohort) Antivir Ther 8 suppl 1 2003 337
21. F Van Leth, P Phanuphak, K Ruxrungtham et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial the 2NN study Lancet 363 2004 1253 1263 (Pubitemid 38496486)
22. JE Gallant, E Dejesus, JR Arribas et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV N Engl J Med 354 2006 251 260 (Pubitemid 43113030)
23. VA Johnson, F Brun-Vézinet, B Clotet et al. Update of the drug resistance mutations in HIV-1: December 2009 Top HIV Med 17 2009 138 145
24. LC Mbuagbaw, JH Irlam, A Spaulding, GW Rutherford, N Siegfried Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals Cochrane Database Syst Rev 8 2010 CD004246.
25. E DeJesus, D McCarty, CF Farthing et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial Clin Infect Dis 39 2004 411 418 (Pubitemid 39050491)
26. E DeJesus, G Herrera, E Teofilo et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 2004 1038 1046 (Pubitemid 39313463)
27. GJ Moyle, E DeJesus, P Cahn et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study J Acquir Immune Defic Syndr 38 2005 417 425 (Pubitemid 40381551)
28. AL Pozniak, JE Gallant, E DeJesus et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis J Acquir Immune Defic Syndr 43 2006 535 540 (Pubitemid 44885619)
29. JL Lennox, E DeJesus, A Lazzarin et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
30. Rimsky L, Eron J, Clotet B, et al. Characterization of the resistance profile of TMC278: 48-week analysis of the phase III studies ECHO and THRIVE. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, USA; Sept 12-15, 2010. Abstract H-1810.
31. OF Laterza, CP Price, MG Scott Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48 2002 699 707 (Pubitemid 34439101)
32. Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J. Prevalence of genotypic and phenotypic susceptibility to etravirine in US samples received for routine resistance testing. 18th International AIDS Conference; Vienna, Austria; July 18-23, 2010. Abstract MOPDB105.
33. P Menezes, JJ Eron Jr, PA Leone, AA Adimora, DA Wohl, WC Miller Recruitment of HIV/AIDS treatment-naive patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race HIV Med 12 2011 183 191
34. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race analyses on week 48 safety and efficacy findings in treatment-naive, HIV-1-infected patients enrolled in ECHO and THRIVE. 48th Annual Meeting of the Infectious Diseases Society of America; Vancouver, Canada; Oct 21-24, 2010. Abstract 1124.
35. M Nelson, G Amaya, N Clumeck et al. Efficacy and safety of TMC278 in treatment-naive, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials J Int AIDS Soc 13 suppl 4 2010 P210